Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia, JY Han, J Molina, ...
The Lancet 387 (10027), 1540-1550, 2016
6737 2016 Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ...
The Lancet 393 (10183), 1819-1830, 2019
2983 2019 Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ...
The Lancet 394 (10212), 1915-1928, 2019
2435 2019 Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study EEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, ...
The Lancet 393 (10167), 156-167, 2019
1398 2019 Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients E de Azambuja, F Cardoso, G de Castro, M Colozza, MS Mano, ...
British journal of cancer 96 (10), 1504-1513, 2007
1309 2007 First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ...
The Lancet 389 (10072), 917-929, 2017
1222 2017 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial D Cameron, MJ Piccart-Gebhart, RD Gelber, M Procter, A Goldhirsch, ...
The Lancet 389 (10075), 1195-1205, 2017
1101 2017 Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum … JPH Machiels, RI Haddad, J Fayette, LF Licitra, M Tahara, JB Vermorken, ...
The Lancet Oncology 16 (5), 583-594, 2015
464 * 2015 Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 K Cocks, MT King, G Velikova, G de Castro Jr, MM St-James, PM Fayers, ...
European journal of cancer 48 (11), 1713-1721, 2012
456 2012 Side effects of approved molecular targeted therapies in solid cancers C Widakowich, G de Castro Jr, E De Azambuja, P Dinh, A Awada
The oncologist 12 (12), 1443-1455, 2007
408 2007 Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ...
The Lancet Oncology 21 (12), 1574-1588, 2020
406 2020 Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024 … K Nosaki, H Saka, Y Hosomi, P Baas, G de Castro Jr, M Reck, YL Wu, ...
Lung Cancer 135, 188-195, 2019
251 2019 Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS)≥ 1%: open-label … G Lopes, YL Wu, I Kudaba, D Kowalski, BC Cho, G Castro, ...
Journal of Clinical Oncology 36 (18_suppl), LBA4-LBA4, 2018
249 2018 Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation P Lothaire, E de Azambuja, D Dequanter, Y Lalami, C Sotiriou, G Andry, ...
Head & Neck: Journal for the Sciences and Specialties of the Head and Neck …, 2006
225 2006 Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer CM Carnielli, CCS Macedo, T De Rossi, DC Granato, C Rivera, ...
Nature communications 9 (1), 3598, 2018
172 2018 KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G De Castro, ...
Annals of Oncology 29, viii729, 2018
165 2018 Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study KJ Harrington, B Burtness, R Greil, D Soulières, M Tahara, G de Castro Jr, ...
Journal of Clinical Oncology 41 (4), 790-802, 2023
162 2023 Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised … L Paz-Ares, J Mezger, TE Ciuleanu, JR Fischer, J von Pawel, M Provencio, ...
The Lancet Oncology 16 (3), 328-337, 2015
151 2015 Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell … D Rischin, KJ Harrington, R Greil, D Soulieres, M Tahara, G de Castro, ...
Journal of Clinical Oncology 37 (15_suppl), 6000-6000, 2019
148 2019 Constraints on models of scalar and vector leptoquarks decaying to a quark and a neutrino at AM Sirunyan, A Tumasyan, W Adam, F Ambrogi, E Asilar, T Bergauer, ...
Physical Review D 98 (3), 032005, 2018
147 2018